Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

Authors: Buchbinder, Elizabeth I., Dutcher, Janice P., Daniels, Gregory A., Curti, Brendan D., Patel, Sapna P., Holtan, Shernan G., Miletello, Gerald P., Fishman, Mayer N., Gonzalez, Rene, Clark, Joseph I., Richart, John M., Lao, Christopher D., Tykodi, Scott S., Silk, Ann W., McDermott, David F.

Source: Journal for immunotherapy of cancer. 7(1)

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100132527841.0x000001&indx=1&recIds=ETOCvdc_100132527841.0x000001

Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2 .

Authors: Clark, Joseph I., Curti, Brendan, Davis, Elizabeth J., Kaufman, Howard, Amin, Asim, Alva, Ajjai, Logan, Theodore F., Hauke, Ralph, Miletello, Gerald P., Vaishampayan, Ulka, Johnson, Douglas B., White, Richard L., Wiernik, Peter H., Dutcher, Janice P.

Source: Journal of Investigative Medicine (Sage Publications Inc.); Apr2021, Vol. 69 Issue 4, p888-892, 5p

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.